Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095719 · ClinicalTrials.gov registry record · Phase 3
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia
A Phase 3 study of Dementia and Alzheimers Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
- 14
- Study locations
NCT00095719: Completed Phase 3 study of Dementia and Alzheimers Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00095719 is a Phase 3 study of Dementia and Alzheimers Disease that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 125 participants, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (98% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00095719, a Phase 3 study of Dementia and Alzheimers Disease, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this trial is to test the safety \& tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aripiprazole
Study Locations (14)
Florida
- Local Institution - Hialeah
- Local Institution - Miami
- Local Institution - North Miami
New York
- Local Institution - New York
- Local Institution - Staten Island
Oklahoma
- Local Institution - Oklahoma City
- Local Institution - Tulsa
California
- Local Institution - Santa Ana
Connecticut
- Local Institution - Hamden
Indiana
- Local Institution - Indianapolis
Ohio
- Local Institution - Dayton
Pennsylvania
- Local Institution - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
What the finished NCT00095719 record still lists
NCT00095719 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Dementia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00095719 lists 14 locations in 10 states (Florida, New York, Oklahoma).
Frequently Asked Questions
What is clinical trial NCT00095719 about?
NCT00095719 is a clinical study titled "Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia". The purpose of this trial is to test the safety \& tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.
What is the current status of trial NCT00095719?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2003-12. Estimated completion is 2005-03.
What conditions does trial NCT00095719 study?
This clinical trial studies the following conditions: Dementia, Alzheimers Disease.
What interventions are being tested in trial NCT00095719?
The interventions under investigation include: Placebo (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00095719?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00095719 being conducted?
This trial has 14 study locations across California, Connecticut, Florida, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00095719's enrollment target sits among peer trials
125 107th of 199 higher than 93 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACHIEVE Brain Health Follow-Up Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
ACTIVE NOT RECRUITING · Phase 3
-
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Escitalopram for Agitation in Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Preventing Cognitive Decline With Alternative Therapies
COMPLETED · Phase 3
-
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia